Jeong-Yoon Choi1, Woo-Keun Seo2, Sung Hoon Kang1, Jin-Man Jung1, Kyung-Hee Cho1, Sungwook Yu1, Kyungmi Oh1. 1. From the Department of Neurology, Korea University Ansan Hospital, Ansan, GyeongGi Province, Korea (J.-Y.C., J.-M.J.); Department of Neurology, Korea University Guro Hospital, Seoul, Korea (W.-K.S., S.H.K., K.O.); and Department of Neurology, Korea University Anam Hospital, Seoul, Korea (K.-H.C., S.Y.). 2. From the Department of Neurology, Korea University Ansan Hospital, Ansan, GyeongGi Province, Korea (J.-Y.C., J.-M.J.); Department of Neurology, Korea University Guro Hospital, Seoul, Korea (W.-K.S., S.H.K., K.O.); and Department of Neurology, Korea University Anam Hospital, Seoul, Korea (K.-H.C., S.Y.). nukseo@korea.ac.kr.
Abstract
BACKGROUND AND PURPOSE: The objective of this study was to investigate the potential benefits of statin therapy on mortality and stroke recurrence after cardioembolic stroke. METHODS: In this retrospective observational study, we analyzed data from 535 patients with first-ever cardioembolic stroke. Patients were classified into nonstatin, low-potency statin, and high-potency statin groups. The primary outcomes were time to mortality and time to recurrent stroke. RESULTS: The mean duration of follow-up was 22.2 months. The cumulative mortality rate was 7% at the end of the first year and 10% at the end of the third year. Statin therapy was independently associated with reduced mortality (hazard ratio, 0.237; 95% confidence interval, 0.080-0.703 for nonstatin versus low-potency statin; hazard ratio, 0.158; 95% confidence interval, 0.037-0.686 for nonstatin versus high-potency statin). Statin treatment did not affect the incidence of recurrent stroke in patients with cardioembolic stroke. CONCLUSIONS: Statin therapy could be associated with reduced mortality in patients with cardioembolic stroke.
BACKGROUND AND PURPOSE: The objective of this study was to investigate the potential benefits of statin therapy on mortality and stroke recurrence after cardioembolic stroke. METHODS: In this retrospective observational study, we analyzed data from 535 patients with first-ever cardioembolic stroke. Patients were classified into nonstatin, low-potency statin, and high-potency statin groups. The primary outcomes were time to mortality and time to recurrent stroke. RESULTS: The mean duration of follow-up was 22.2 months. The cumulative mortality rate was 7% at the end of the first year and 10% at the end of the third year. Statin therapy was independently associated with reduced mortality (hazard ratio, 0.237; 95% confidence interval, 0.080-0.703 for nonstatin versus low-potency statin; hazard ratio, 0.158; 95% confidence interval, 0.037-0.686 for nonstatin versus high-potency statin). Statin treatment did not affect the incidence of recurrent stroke in patients with cardioembolic stroke. CONCLUSIONS: Statin therapy could be associated with reduced mortality in patients with cardioembolic stroke.
Authors: Ye Sel Kim; Moo-Seok Park; Jun-Hwa Lee; Jong-Won Chung; Mi Ji Lee; Chi Kyung Kim; Jin-Man Jung; Kyungmi Oh; Oh Young Bang; Geong-Moon Kim; Ji-Mi Choi; Juneyoung Lee; Chin Sang Chung; Kwang Ho Lee; Woo-Keun Seo Journal: Front Neurol Date: 2018-04-24 Impact factor: 4.003